She Qin-Ying, Li Li-Juan, Liu Ming-Hong, Tan Ru-Yu, Zhong Yi-Wen, Bao Jing-Fu, Xie Jie-Dong
Department of Nephrology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, China.
State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Front Pharmacol. 2022 Sep 27;13:1011008. doi: 10.3389/fphar.2022.1011008. eCollection 2022.
Fibroblast growth factor 21 (FGF-21) is an evolutionarily conserved protein that plays multiple roles in metabolic regulation. Over the past two decades, numerous studies have deepened our understanding of its various functions and its pharmacological value. Nevertheless, most clinical trials have not achieved the desired results, which raises issues regarding its clinical value. In this bibliometric analysis, we evaluated the state of FGF-21 research over the last 20 years and identified important topics, achievements, and potential future directions. Publications related to FGF-21 were collected from the Web of Science Core Collection-Science Citation Index Expanded. HistCite, VOSviewer, and CiteSpace were used for bibliometric analysis and visualization, including the analysis of annual publications, leading countries, active institutions and authors, core journals, co-cited references, and keywords. Altogether, 2,490 publications related to FGF-21 were obtained. A total of 12,872 authors from 2,628 institutions in 77 countries or regions reported studies on FGF-21. The United States of America was the most influential country in FGF-21 research. Alexei Kharitonenkov, Steven A. Kliewer, and David J. Mangelsdorf were the most influential scholars, and endocrinology journals had a core status in the field. The physiological roles, clinical translation, and FGF-21-based drug development were the main topics of research, and future studies may concentrate on the central effects of FGF-21, FGF-21-based drug development, and the effects of FGF-21 on non-metabolic diseases. The peripheral metabolic effects of FGF-21, FGF-21-based drug development, and translational research on metabolic diseases are the three major topics in FGF-21 research, whereas the central metabolic effects of FGF-21 and the effects of FGF-21 on metabolic diseases are the emerging trends and may become the following hot topics in FGF-21 research.
成纤维细胞生长因子21（FGF-21）是一种在进化上保守的蛋白质，在代谢调节中发挥多种作用。在过去二十年中，众多研究加深了我们对其各种功能及其药理学价值的理解。然而，大多数临床试验并未取得预期结果，这引发了关于其临床价值的问题。在这项文献计量分析中，我们评估了过去20年FGF-21的研究状况，并确定了重要主题、成果和潜在的未来方向。从科学网核心合集-科学引文索引扩展版中收集了与FGF-21相关的出版物。使用HistCite、VOSviewer和CiteSpace进行文献计量分析和可视化，包括年度出版物分析、主要国家、活跃机构和作者、核心期刊、共被引参考文献和关键词分析。总共获得了2490篇与FGF-21相关的出版物。来自77个国家或地区2628个机构的12872名作者报告了关于FGF-21的研究。美国是FGF-21研究中最具影响力的国家。阿列克谢·哈里托年科夫、史蒂文·A·克利弗和大卫·J·曼格斯多夫是最具影响力的学者，内分泌学杂志在该领域具有核心地位。生理作用、临床转化和基于FGF-21的药物开发是主要研究主题，未来研究可能集中在FGF-21的中枢效应、基于FGF-21的药物开发以及FGF-21对非代谢性疾病的影响。FGF-21的外周代谢效应、基于FGF-21的药物开发以及代谢性疾病的转化研究是FGF-21研究中的三个主要主题，而FGF-21的中枢代谢效应以及FGF-21对代谢性疾病的影响是新兴趋势，可能成为FGF-21研究接下来的热点话题。
